Oliver Leatham, vice president and global head of value and access at Certara, writes about the complex issues that surrounds assigning a value to new drugs.
European Pharmaceutical Manufacturer catches up with Norgine CEO Peter Stein to discuss pharma trends, US and EU drug approvals and the company’s approach to improvement.
Dr Anthony Qu, vice president of scientific affairs at Cambrex and Dr Yanjun Zhao, market intelligence manager examine the complexities of developing oral doses for the paediatric market.
Torkel Gren, Recipharm and Anders Millerhovf, CTC Clinical Trial Consultants discuss the steps needed for drug formulation during first-in-human (FIH) trials, if regulatory approval is to be achieved.
Dr Andrew Rut, CEO of SaaS provider My Meds & Me discusses why AI can revolutionise drug development and healthcare but caution over data is critical for success.
After receiving approval for two HIV drugs, Delstrigo and Pifeltro, Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData.
The US Food and Drug Administration (FDA) has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Here, Dr Sheuli Porkess, deputy chief scientific officer, Association of the British Pharmaceutical Industry (ABPI), outlines how the pharmaceutical industry takes a substance from molecule to medicine and how the process requires persistence.
With worldwide orphan drug sales predicted to grow at a significant rate and each drug fetching a hefty price tag, I look at this market and its drivers in a bit more detail…
A new study from the University of Eastern Finland, published in the European Journal of Clinical Pharmacology, has highlighted that there are differences in the availability of orphan medicines between different European countries.
There is rising tide of drug-resistant microbes that is thought of as one of the greatest threats to public health today, yet the pipeline of new antibiotics is dwindling. Here, Dr Peter Jackson, AMR Centre, discusses what action is needed
Independent consulting group, NDA, has announced its findings from its fifth annual comparison of drug approvals in Europe and the US in preparation for this year’s DIA Europe in Basel, Switzerland.
